NCT06360575View on ClinicalTrials.gov

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 30, 2016

Primary Completion Date

November 15, 2025

Study Completion Date

November 15, 2025

Conditions
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Crizotinib

Given PO

PROCEDURE

Radiologic Examination

Undergo radiologic evaluation

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH